VeriSIM Life Awarded U.S. Government Agreement to Advance New Approach Methodologies for Drug Development

SAN FRANCISCO--(BUSINESS WIRE)--VeriSIM Life today announced that it has entered into an agreement with the Department of War to advance computational New Approach Methodologies (NAMs) for medical countermeasure development and safety assessment.

Under the agreement, VeriSIM Life will use its BIOiSIM® platform to develop and evaluate computational models that integrate biological, experimental, and drug-specific data to better understand how findings from preclinical systems translate to humans.

A key focus of the work is determining where computational approaches can reduce the need for animal studies while maintaining the scientific rigor required for drug development decisions. The program will evaluate how these methods can be used alongside experimental data to guide study design and identify where additional testing is most informative.

“We have spent years building BIOiSIM around one of the most fundamental challenges in drug development: understanding what is likely to translate to humans before committing to more experiments,” said Dr. Jo Varshney, Founder and CEO of VeriSIM Life. “This program gives us an opportunity to apply that work to an important government need and demonstrate where computational methods can meaningfully reduce animal use while improving the quality of translational decisions.”

BIOiSIM combines mechanistic bio simulation with machine learning/AI to evaluate pharmacokinetics, safety, efficacy, and other factors that influence therapeutic translation. VeriSIM Life has applied the platform across discovery and development programs and has worked with pharmaceutical companies, research institutions, and government agencies to evaluate and validate computational approaches to drug development.

The agreement expands VeriSIM Life’s work in NAMs and reflects the growing effort across government and industry to develop more human-relevant approaches to preclinical research. Investment and implementation of NAM technologies will reduce animal use and enable the acceleration of medical countermeasure development and delivery to meet operational and mission needs across the conflict continuum.

About VeriSIM Life

VeriSIM Life develops computational technologies to reduce uncertainty and improve development efficiency from design to clinic. Its BIOiSIM® platform combines mechanistic biosimulation, biological data, and machine learning to support translational decision-making throughout drug discovery and development.

Government Acknowledgement

This project has been funded in part by the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense’s (CPE CBRND) Joint Project Lead for CBRN Enabling Technologies (JPL CBRN ET) under Agreement W911SR-26-9-A036.